FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Titel:
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Auteur:
Sahin, U. Türeci, Ö. Manikhas, G. Lordick, F. Rusyn, A. Vynnychenko, I. Dudov, A. Bazin, I. Bondarenko, I. Melichar, B. Dhaene, K. Wiechen, K. Huber, C. Maurus, D. Arozullah, A. Park, J.W. Schuler, M. Al-Batran, S.-E.